Photo taken from Carl Ola Landgren/Twitter
Apr 26, 2024, 14:15
Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker
Carl Ola Landgren, Chief of the Myeloma Division and Translational Clinical Oncology Program at Sylvester Comprehensive Cancer Center, shared a post on X/Twitter:
“With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients’ access to new therapies will be much quicker.
Instead of waiting for 10-15 years, new drugs can be available in 3-5 years. Here is how it works.”
Source: Carl Ola Landgren/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 3, 2025, 04:57
May 3, 2025, 04:19
May 3, 2025, 04:17